New Dual-Action drug shows promise in advanced lung cancer trial
NCT ID NCT04995523
First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 29 times
Summary
This study tests an experimental drug called AZD2936 in people with advanced or metastatic non-small cell lung cancer (NSCLC) that has not responded to other treatments. The drug is a bispecific antibody designed to block two proteins (TIGIT and PD-1) that help cancer hide from the immune system, potentially boosting the body's ability to fight the cancer. The trial involves about 212 participants and aims to find the safest dose and see if the drug can shrink tumors or slow disease progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Site
Chicago, Illinois, 60637, United States
-
Research Site
Rochester, Minnesota, 55905, United States
-
Research Site
Fairfax, Virginia, 22031, United States
-
Research Site
Melbourne, 3000, Australia
-
Research Site
Anderlecht, 1070, Belgium
-
Research Site
Leuven, 3000, Belgium
-
Research Site
Florianópolis, 88034-000, Brazil
-
Research Site
Natal, 59075-740, Brazil
-
Research Site
Porto Alegre, 90035903, Brazil
-
Research Site
Rio de Janeiro, 20231-050, Brazil
-
Research Site
São Paulo, 01246-000, Brazil
-
Research Site
Chengdu, 610041, China
-
Research Site
Chongqing, 400030, China
-
Research Site
Copenhagen, 2100, Denmark
-
Research Site
Dijon, 21079, France
-
Research Site
Toulouse, 31059, France
-
Research Site
Tbilisi, 0112, Georgia
-
Research Site
Kashiwa, 227-8577, Japan
-
Research Site
Niigata, 951-8566, Japan
-
Research Site
Sendai, 981-0914, Japan
-
Research Site
Tokyo, 104-0045, Japan
-
Research Site
Kuala Lumpur, 59100, Malaysia
-
Research Site
Kuching, 93586, Malaysia
-
Research Site
Chisinau, MD-2025, Moldova
-
Research Site
Groningen, 9713 GZ, Netherlands
-
Research Site
Leiden, 2333 ZA, Netherlands
-
Research Site
Utrecht, 3584 CX, Netherlands
-
Research Site
Seoul, 03082, South Korea
-
Research Site
Seoul, 03722, South Korea
-
Research Site
Seoul, 05505, South Korea
-
Research Site
Barcelona, 08035, Spain
-
Research Site
Madrid, 28027, Spain
-
Research Site
Madrid, 28041, Spain
-
Research Site
Taichung, 40201, Taiwan
-
Research Site
Taichung, Taiwan
-
Research Site
Tainan, 70403, Taiwan
-
Research Site
Taipei, 110, Taiwan
-
Research Site
Bangkok, 10700, Thailand
-
Research Site
Chanthaburi, 22000, Thailand
-
Research Site
Muang, 50200, Thailand
Conditions
Explore the condition pages connected to this study.